Phase 3 N=467 Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.05; -1.36 percentage of glycosylated haemoglobin
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=144 Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Adult Acute Megakaryoblastic Leukemia · Adult Acute Monocytic Leukemia
Primary: Disease-free Survival — 8.87; 5.26 months — p=0.026
Phase 3 N=248 A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy
Atrial Fibrillation
Primary: Number of Participants With Incidence of Post-Procedure Major Bleeding Events — 0; 0; 0; 1 Participants
Phase 3 N=28 Steroid Withdrawal in Pediatric Renal Transplant: Impact on Growth, Bone Metabolism and Acute Rejection
Kidney Diseases
Primary: Stimulation of Growth After 12 Months (Delta Z-score) — 1.2; 0.6 units on a scale
Phase 3 N=426 Persistency Study After Hib-CRM (Cross-Reacting Material)197 or Hib-TT (Tetanus Toxoid) Vaccines in Chinese Children
Meningitis, Epiglottitis, Pneumonia, Arthritis Caused by Haemophilus Influenzae Type b
Primary: Geometric Mean Anti-PRP (Polyribosyl Ribitol Phosphate) Concentrations at Day 1 (4 Years Post Booster Dose Administered in Study V37_07E1) — 2.66; 5.05 Concentration in…
Phase 3 N=761 Evaluation of Ceftaroline Fosamil Versus Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections
Complicated Skin and Soft Tissue Infection
Primary: Clinical Response at Test of Cure (TOC) in Modified Intent-to-treat (MITT) Analysis Set — 396; 202; 58; 34 Participant
Phase 3 N=145 High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly
Atherosclerosis · Cardiovascular Disease
Primary: Changes in Plaque Architecture and Composition Directly Measured by Magnetic Resonance Imaging (MRI) in the Aorta and Carotid Arteries — 7; 5 percentage of internal…
Phase 3 N=185 Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Mean Worse Eye Intraocular Pressure (IOP) Analyzed by Two-Sample T-Test — 25.42; 24.43; -10.45; -8.28 Millimeters of Mercury (mmHg)
Phase 3 N=534 Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies
Chronic Hepatitis C
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 71.9; 77.5; 82.6 percentage of participants
Phase 3 N=316 Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
Hypercholesterolemia
Primary: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis — -2.3; -48.2 percent change — p=<0.0001
Phase 3 N=720 Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)
Hypercholesterolemia
Primary: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis — -50.6; -20.7 percent change — p=<0.0001
Phase 3 N=3,420 Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy
Breast Cancer
Primary: Time to First Clinical Fracture — NA; NA Days — p=<0.0001
Phase 3 N=570 Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma
Primary: Progression Free Survival (PFS) Per Independent Central Radiology Review — 3.7; 3.6 Months
Phase 3 N=103 Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia
Hypercholesterolemia
Primary: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis — -15.6; -47.2 percent change — p=<0.0001
Phase 3 N=120 Efficacy and Safety of IQP-VV-102 in Weight Management
Obesity · Overweight
Primary: Change in Body Weight at End of Study Compared to Baseline — 3.29; 0.83 kg